Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952858 | 0.82 | DAO (0.43) | DAOAURKAAURKBINCENPGAA | |
| SCHEMBL4277237 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2GAAADRA2BADRA2C | |
| SCHEMBL5202931 | 0.77 | AURKA (0.44) | DAOAURKAAURKBINCENPGAA | |
| SCHEMBL6641176 | 0.77 | — | — | |
| SCHEMBL5691773 | 0.76 | HDAC8 (0.42) | GABRA1GABRB2GAAADRA2BADRA2C | |
| SCHEMBL8718496 | 0.74 | GABRA1 (0.48) | DAOGABRA1GABRB2GAAKDM4E | |
| SCHEMBL797191 | 0.74 | — | — | |
| SCHEMBL5685566 | 0.74 | — | — | |
| SCHEMBL16759805 | 0.73 | DAO (0.43) | DAOAURKAAURKBINCENPGAA | |
| SCHEMBL1694688 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-2681215-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-08 | — | — | EP | claimed |
| WO-2013131010-A2 | FUNCTION OF CHEMOKINE RECEPTOR CCR8 IN MELANOMA METASTASIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2013-09-06 | — | — | WO | claimed |
| WO-2012118850-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | claimed |
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | claimed |
| EP-1869045-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006107254-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | claimed |
| US-6599942-B1 | Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | claimed |
| JP-2002540189-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-20020107390-A1 | Thyromimetic organic compounds | KUKKOLA PAIVI J (US) | 2002-08-08 | — | — | US | claimed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | claimed |
| EP-1165502-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058279-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | claimed |
| CN-117642399-A | Pyrrolopyridone derivatives useful for the treatment of cancer | 泰治疗有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-107973748-A | Pyridinone azo dispersion dyes and its synthetic method containing sulfonate group or sulfoamido | 潘劲松 | 2018-05-01 | — | — | CN | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-0508215-B1 | Process for the preparation of 2-chloro-pyridines | BAYER AG (DE) | 1996-05-15 | — | — | EP | disclosed |
| US-5283338-A | Process for the preparation of 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-01 | — | — | US | disclosed |
| EP-0508215-A1 | Process for the preparation of 2-chloro-pyridines | BAYER AG (DE) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053969-A1 | NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR3 | DAO 4286/4885AURKA 3417/4885AURKB 2939/4885 |
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | DAO 458/4885AURKA 3382/4885AURKB 3839/4885 |
| US-20020107390-A1 | Thyromimetic organic compounds | TSHR, NR1H3, NR1H2 | DAO 527/4885AURKA 3268/4885AURKB 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.